The discrimination between samples with high and low HH/GLI pathway activity exhibited the expected overlap with classified BCC and normal skin samples, respectively, and thus validated our inferred signature (Fig. 6B, S9G). This evidence concerns the gene GLI1 and skin basal cell carcinoma.